Document:

Form of Indemnification Agreement

 Exhibit 10.1 
 INDEMNIFICATION AGREEMENT 
 AGREEMENT, made this ____ day of ______, 2007, between Jazz
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”). 
 W I
T N E S S E T H: 
 WHEREAS, the Indemnitee is a director and/or officer of the
Company. 
 WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless
they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation. 
 WHEREAS, in recognition of Indemnitee’s need for substantial protection against personal liability in order to enhance Indemnitee’s continued
service to the Company in an effective manner and Indemnitee’s reliance on the provisions of the Company’s Certificate of Incorporation (“Certificate of Incorporation”) and the Company’s Bylaws (the “Bylaws”)
requiring indemnification of the Indemnitee to the fullest extent permitted by law, and in part to provide Indemnitee with specific contractual assurance that the protection promised by such Certificate of Incorporation and Bylaws will be available
to Indemnitee (regardless of, among other things, any amendment to or revocation of such Certificate of Incorporation or Bylaws or any change in the composition of the Company’s Board of Directors or acquisition transaction relating to the
Company), the Company wishes to provide in this Agreement for the indemnification of and the advancing of expenses to Indemnitee to the fullest extent (whether partial or complete) permitted by law and as set forth in this Agreement. 
 [WHEREAS, the Company and Indemnitee entered into an Indemnification Agreement dated ______, 2003 (the “Prior Indemnification
Agreement”), at which time the Company was a California corporation.] 
 [WHEREAS, the Company subsequently reincorporated in the
State of Delaware.] 
 WHEREAS, the Certificate of Incorporation, the Bylaws and the General Corporation Law of the State of Delaware
(“DGCL”) expressly provide that the indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other
persons with respect to indemnification. 
 WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself
to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified. 

 WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and
Bylaws and any resolutions adopted pursuant thereto and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. 
 [WHEREAS, the Company and Indemnitee desire to supersede and replace the Prior Indemnification Agreement with this Agreement.] 
 NOW, THEREFORE, in consideration of the premises and of Indemnitee agreeing to serve or continuing to serve the Company directly or, at its request, with another enterprise, and intending to be legally bound hereby,
the parties hereto agree as follows: 
 Section 1. Basis Indemnification Agreement. (a) In the event Indemnitee
was, is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, a Claim (as defined in Section 9(b) herein) by reason of (or arising in part out of) an Indemnifiable
Event (as defined in Section 9(d) herein), the Company shall indemnify Indemnitee (including its respective directors, officers, partners, members, employees and agents, as applicable) and each person who controls any of them or who may be
liable within the meaning of Section 15 the Securities Act of 1933, as amended (the “Securities Act”) or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the fullest extent
permitted by law as soon as practicable but in any event no later than 30 days after written demand is presented to the Company, against any and all Expenses (as defined in Section 9(c) herein), judgments, fines, penalties and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection therewith) of such Claim actually and reasonably incurred by or on behalf of Indemnitee in connection with such Claim and any federal, state, local or
foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement. If requested by Indemnitee in writing, the Company shall advance (within ten business days of such written request) any and all
Expenses to Indemnitee (an “Expense Advance”). Notwithstanding anything in this Agreement to the contrary, and except as provided in Section 3, prior to a Change of Control (as defined in Section 9(a) herein), Indemnitee shall
not be entitled to indemnification pursuant to this Agreement in connection with any Claim (i) initiated by Indemnitee against the Company or any director or officer of the Company unless the Company has joined in or consented to the initiation
of such Claim, or (ii) made on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to the Company or its stockholders or is an act or omission not in good faith or which involves intentional
misconduct or a knowing violation of the law. 
 (b) Notwithstanding the foregoing, (i) the indemnification obligations of the Company
under Section 1(a) shall be subject to the condition that the Reviewing Party shall not have determined (in a written opinion, in any case in which the special independent counsel referred to in Section 2 hereof is involved) that
Indemnitee would not be permitted to be indemnified under applicable law, and (ii) the obligation of the Company to make an Expense Advance pursuant to Section 1(a) shall be subject to the condition that the Company receives an undertaking
that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled 

  

 2 

 
to be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has
commenced legal proceedings in the Court of Chancery of the State of Delaware (the “Delaware Court”) to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that
Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect thereto (as
to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s obligation to reimburse the Company for Expense Advances shall be unsecured and no interest shall be charged thereon. If there has not been a Change in
Control, the Reviewing Party shall be selected by the Board of Directors, and if there has been such a Change in Control, the Reviewing Party shall be the special independent counsel referred to in Section 2 hereof. If there has been no
determination by the Reviewing Party or if the Reviewing Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law, Indemnitee shall have the right to commence litigation in the
Delaware Court seeking an initial determination by the court or challenging any such determination by the Reviewing Party or any aspect thereof and the Company hereby consents to service of process and to appear in any such proceeding. Any
determination by the Reviewing Party otherwise shall be conclusive and binding on the Company and Indemnitee. 
 Section 2.
Change in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has been approved by two- thirds or more of the Company’s Board of Directors who were directors
immediately prior to such Change in Control) then with respect to all matters thereafter arising concerning the rights of Indemnitee to indemnity payments and Expense Advances under this Agreement or any other agreement, the Bylaws or Certificate of
Incorporation now or hereafter in effect relating to Claims for Indemnifiable Events, the Company shall seek legal advice only from special independent counsel selected by Indemnitee and approved by the Company (which approval shall not be
unreasonably withheld or delayed) and who has not otherwise performed services for the Company within the last five years (other than in connection with such matters) or for Indemnitee. In the event that Indemnitee and the Company are unable to
agree on the selection of the special independent counsel, such special independent counsel shall be selected by lot from among at least five law firms with offices in the State of Delaware having more than fifty attorneys, having a rating of
“av” or better in the then current Martindale Hubbell Law Directory and having attorneys which specialize in corporate law. Such selection shall be made in the presence of Indemnitee (and his legal counsel or either of them, as Indemnitee
may elect). Such counsel, among other things, shall, within 90 days of its retention, render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law. The
Company agrees to pay the reasonable fees of the special independent counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, and damages arising out of or
relating to this Agreement or its engagement pursuant hereto. 
 Section 3. Indemnification for Additional
Expenses. The Company shall indemnify Indemnitee against any and all expenses (including attorneys’ fees) and, if requested by Indemnitee in writing, shall (within ten business days of such written request) advance such 

  

 3 

 
expenses to Indemnitee, which are incurred by Indemnitee in connection with any Claim asserted against or action brought by Indemnitee for
(i) indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect relating to Claims for Indemnifiable Events and/or
(ii) recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advance expense payment or
insurance recovery, as the case may be. The Indemnitee shall qualify for advances solely upon the execution and delivery to the Company of an undertaking providing that the Indemnitee undertakes to repay the advance to the extent that it is
ultimately determined that the Indemnitee is not entitled to be indemnified by the Company. 
 Section 4. Partial Indemnity,
Etc. If Indemnitee is entitled under any provisions of this Agreement to indemnification by the Company of some or a portion of the Expenses, liabilities, judgments, fines, penalties and amounts paid in settlement of a Claim but not,
however, for all of the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Moreover, notwithstanding any other provision of this Agreement, to the extent that Indemnitee
has been successful on the merits or otherwise in defense of any or all Claims relating in whole or in part to an Indemnifiable Event or in defense of any issue or matter therein, including dismissal without prejudice, Indemnitee shall be
indemnified against all Expenses incurred in connection therewith. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder the burden of proof shall be on the Company
to establish that Indemnitee is not so entitled. 
 Section 5. No Presumption. For purposes of this Agreement, the
termination of any action, suit or proceeding by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that Indemnitee did not meet
any particular standard of conduct or have any particular belief. 
 Section 6. Notification and Defense of
Claim. Within 30 days after receipt by Indemnitee of notice of the commencement of a Claim which may involve an Indemnifiable Event, Indemnitee will, if a claim in respect thereof is to be made against the Company under this Agreement,
submit to the Company a written notice identifying the proceeding, but the omission so to notify the Company will not relieve it from any liability which it may have to Indemnitee under this Agreement unless the Company is materially prejudiced by
such lack of notice. With respect to any such Claim as to which Indemnitee notifies the Company of the commencement thereof: 
 (a) the
Company will be entitled to participate therein at its own expense; 
 (b) except as otherwise provided below, to the extent that it may
wish, the Company jointly with any other indemnifying party similarly notified will be entitled to assume the defense thereof, with counsel satisfactory to Indemnitee. After notice from the Company to Indemnitee of its election to assume the defense
thereof, the Company will not be liable to Indemnitee under this Agreement for any legal or other expenses subsequently incurred by 

  

 4 

 
Indemnitee in connection with the defense thereof other than reasonable costs of investigation or as otherwise provided below. Indemnitee shall have the
right to employ its own counsel in such action, suit or proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of Indemnitee unless (i) the
employment of counsel by Indemnitee has been authorized by the Company, (ii) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense of such
action, or (iii) the Company shall not in fact have employed counsel to assume the defense of such action, in each of which cases the fees and expenses of counsel shall be at the expense of the Company. The Company shall not be entitled to
assume the defense of any claim brought by or on behalf of the Company or as to which Indemnitee shall have made the conclusion provided for in clause (ii) above; and 
 (c) the Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any action or claim effected
without its written consent. The Company shall not settle any action or claim in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee’s written consent. Neither the Company nor Indemnitee will unreasonably
withhold or delay their consent to any proposed settlement. 
 Section 7. Non-exclusivity, Etc. The rights of
Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under the Certificate of Incorporation, the Bylaws, the DGCL, any agreement, a vote of the stockholders, a resolution of directors or otherwise. No amendment,
alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee acting on behalf of the Company and at the request of
the Company prior to such amendment, alteration or repeal. To the extent that a change in the DGCL (whether by statute or judicial decision), the Certificate of Incorporation or the Bylaws permits greater indemnification by agreement than would be
afforded currently under the Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein
conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.
The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. Notwithstanding anything to the contrary herein, the indemnification provided under
this agreement shall continue as to the Indemnitee for any action the Indemnitee took or did not take while serving in an indemnified capacity even though the Indemnitee may have ceased to serve in such capacity. 
 Section 8. Liability Insurance. To the extent the Company maintains an insurance policy or policies providing directors’ and
officers’ liability insurance, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any Company director or officer. If, at the time the Company
receives notice from any source of a Claim as to which Indemnitee is a party or a participant (as a witness or otherwise), the Company has director and officer liability insurance 

  

 5 

 
in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies.
The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Claim in accordance with the terms of such policies. 
 Section 9. Certain Definitions. 
 (a) Change in Control: shall be deemed to have occurred if: 
 (i) before the Company has a class of securities
registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”): 
 (A) the Company, or
any material subsidiary of the Company, is merged, consolidated or reorganized into or with another corporation or other legal person (an “Acquiring Person”) or securities of the Company are exchanged for securities of an Acquiring Person,
and as a result of such merger, consolidation, reorganization or exchange less than a majority of the combined voting power of the then outstanding securities of the Acquiring Person immediately after such transaction are held, directly or
indirectly, in the aggregate by the holders of Voting Securities immediately prior to such transaction; 
 (B) the Company, or
any material subsidiary of the Company, in any transaction or series of related transactions, sells or otherwise transfers all or substantially all of its assets to an Acquiring Person, and less than a majority of the combined voting power of the
then outstanding securities of the Acquiring Person immediately after such sale or transfer are held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such sale or transfer; 
 (C) during any period of two consecutive years, individuals who at the beginning of any such period constitute the directors of the
Company cease for any reason to constitute at least a majority thereof, unless the election, or the nomination for election by the Company’s stockholders, of each director of the Company first elected during such period was approved by a
unanimous vote of the directors of the Company then still in office who were directors of the Company at the beginning of any such period; 
 (D) the Company and its subsidiaries, in any transaction or series of related transactions, sells or otherwise transfers business operations that generated two thirds or more of the consolidated revenues (determined
on the basis of the Company’s four most recently completed fiscal quarters) of the Company and its subsidiaries immediately prior thereto; or 
  

 6 

 (E) any other transaction or series of related transactions occur that have substantially
the effect of the transactions specified in any of the preceding clauses in this paragraph (i); or 
 (ii) after the Company
has a class of securities registered under Section 12 of the Exchange Act: 
 (A) any person, as that term is used in
Section 13(d) and Section 14(d)(2) of the Exchange Act, becomes, is discovered to be, or files a report on Schedule 13D or 14D-1 (or any successor schedule, form or report) disclosing that such person is a beneficial owner (as defined
in Rule 13d-3 under the Exchange Act or any successor rule or regulation), directly or indirectly, of securities of the Company representing 20% or more of the total voting power of the Company’s then outstanding Voting Securities (unless
such person becomes such a beneficial owner in connection with the initial public offering of the Company); 
 (B) individuals
who, as of the consummation date of the Company’s initial public offering, constitute the Board of Directors of the Company cease for any reason to constitute at least a majority of the Board of Directors of the Company, unless any such change
is approved by a unanimous vote of the members of the Board of Directors of the Company in office immediately prior to such cessation; 
 (C) the Company, or any material subsidiary of the Company, is merged, consolidated or reorganized into or with an Acquiring Person or securities of the Company are exchanged for securities of an Acquiring Person, and
immediately after such merger, consolidation, reorganization or exchange less than a majority of the combined voting power of the then outstanding securities of the Acquiring Person immediately after such transaction are held, directly or
indirectly, in the aggregate by the holders of Voting Securities immediately prior to such transaction; 
 (D) the Company, or
any material subsidiary of the Company, in any transaction or series of related transactions, sells or otherwise transfers all or substantially all of its assets to an Acquiring Person, and less than a majority of the combined voting power of the
then outstanding securities of the Acquiring Person immediately after such sale or transfer is held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such sale or transfer; 
  

 7 

 (E) the Company and its subsidiaries, in any transaction or series of related
transactions, sells or otherwise transfers business operations that generated two thirds or more of the consolidated revenues (determined on the basis of the Company’s four most recently completed fiscal quarters) of the Company and its
subsidiaries immediately prior thereto; 
 (F) the Company files a report or proxy statement with the Securities and Exchange
Commission pursuant to the Exchange Act disclosing that a change in control of the Company has or may have occurred or will or may occur in the future pursuant to any then existing contract or transaction; or 
 (G) any other transaction or series of related transactions occur that have substantially the effect of the transactions specified in any
of the preceding clauses in this paragraph (ii). 
 Notwithstanding the provisions of Section 9(a)(ii)(A) or 9(a)(ii)(D), unless
otherwise determined in a specific case by majority vote of the Board of Directors of the Company, a Change of Control shall not be deemed to have occurred for purposes of this Agreement solely because (i) the Company, (ii) an entity in
which the Company directly or indirectly beneficially owns 50% or more of the voting securities or (iii) any Company sponsored employee stock ownership plan, or any other employee benefit plan of the Company, either files or becomes obligated
to file a report or a proxy statement under or in response to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or any successor schedule, form or report or item therein) under the Exchange Act, disclosing beneficial
ownership by it of shares of stock of the Company, or because the Company reports that a Change in Control of the Company has or may have occurred or will or may occur in the future by reason of such beneficial ownership. 
 (b) Claim: any threatened, pending or completed action, suit, proceeding or alternative dispute resolution mechanism, or any inquiry, hearing or
investigation whether conducted by the Company or any other party, whether civil, criminal, administrative, investigative or other. 
 (c)
Expenses: include attorneys’ fees and all other costs, fees, expenses and obligations of any nature whatsoever paid or incurred in connection with investigating, defending, being a witness in or participating in (including appeal), or
preparing to defend, be a witness in or participate in any Claim relating to any Indemnifiable Event. 
 (d) Indemnifiable Event: any
event or occurrence (whether before or after the date hereof) related to the fact that Indemnitee is or was a director, officer, employee, consultant, 

  

 8 

 
agent or fiduciary of or to the Company, or is or was serving at the request of the Board of Directors as a director, officer, employee, trustee, agent or
fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise, or by reason of anything done or not done by Indemnitee in any such capacity including, without limitation, any claim or investigation
under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise on which relate directly to indirectly to the registration, purchase, sale or ownership of any securities of the Company or
to any fiduciary obligation owed with respect thereto or as a direct or indirect result of any claim made by any stockholder of the Company against Indemnitee and arising out of or related to any round of financing of the Company (including but not
limited to claims regarding non-participation, or non-pro rata participation, in such round by such stockholder), or made by a third party against Indemnitee based on any misstatement or omission of a material fact by the Company in violation of any
duty of disclosure imposed on the Company by federal or state securities or common laws. 
 (e) Reviewing Party: (i) the
Company’s Board of Directors (provided that a majority of directors are not parties to the particular Claim for which Indemnitee is seeking indemnification) or (ii) any other person or body appointed by the Company’s Board of
Directors, who is not a party to the particular Claim for which Indemnitee is seeking indemnification, or (iii) if there has been a Change in Control, the special independent counsel referred to in Section 2 hereof. 
 (f) Voting Securities: any securities of the Company which vote generally in the election of directors. 
 Section 10. Amendments, Termination and Waiver. No supplement, modification, amendment or termination of this Agreement shall be
binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver
constitute a continuing waiver. 
 Section 11. Subrogation. In the event of payment under this Agreement, the Company
shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents
necessary to enable the Company effectively to bring suit to enforce such rights. 
 Section 12. No Duplication of
Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment (under insurance policy, Certificate of
Incorporation or otherwise) of the amounts otherwise indemnifiable hereunder. 
 Section 13. Attorneys’ Fees. In the
event that any action is instituted by the Indemnitee under this Agreement or under any liability insurance policies maintained by the Company to enforce or interpret any of the terms hereof or thereof, the Indemnitee shall be 

  

 9 

 
entitled to be paid all Expenses incurred by the Indemnitee with respect to such action if the Indemnitee is ultimately successful in such action. In the
event of an action instituted by or in the name of the Company under this Agreement to enforce or interpret any of the terms of this Agreement, the Indemnitee shall be entitled to be paid Expenses incurred by the Indemnitee in defense of such action
(including costs and expenses incurred with respect to Indemnitee counterclaims and cross-claims made in such action), and shall be entitled to the advancement of Expenses with respect to such action, in each case only to the extent that the
Indemnitee is ultimately successful in such action. 
 Section 14. Binding Effect, Etc. This Agreement shall be
binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the
business and/or assets of the Company, spouse, heirs, and personal and legal representatives. This Agreement shall continue in effect regardless of whether Indemnitee continues to serve as a director or officer (or in one of the capacities
enumerated in Section 9(d) hereof) of the Company or of any other enterprise at the Board of Director’s request. 
 Section 15. Severability. The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any provision within a single section, paragraph or sentence) are held by a
court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain enforceable to the fullest extent permitted by law. 
 Section 16. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by,
and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising
out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive
jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, irrevocably, to the extent such party is not a resident of the State of Delaware, National Corporate
Research, Ltd., 615 South Dupont Highway, City of Dover, County of Kent, Delaware 19901 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such
party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and
agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 
 Section 17. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall
constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 
  

 10 

 Section 18. Entire Agreement. This Agreement constitutes the entire agreement between the
parties regarding the subject matter hereof and supersedes and replaces any and all prior negotiations, correspondence, understandings and agreements, including without limitation the Prior Indemnification Agreement, between the parties regarding
the subject matter hereof. 
 Executed this ___ day of ______, 2007. 
  

			
	Jazz Pharmaceuticals, Inc.
		
	By: 	 	  
	Its:	 	
	
	[Indemnitee]
	
	  

  

 11Employment Agreement by and between the Registrant and Bruce Cozadd

 EXHIBIT 10.2 
 EMPLOYMENT AGREEMENT 
 BY AND BETWEEN 
 JAZZ PHARMACEUTICALS, INC. 
 AND 
 BRUCE C. COZADD 

 TABLE OF CONTENTS 
  

					
	 	  	Page
	 1.
	  	Integration.	  	1
			
	 2.
	  	Definitions.	  	2
			
	 3.
	  	Employment.	  	8
			
	 4.
	  	Compensation of the Executive.	  	9
			
	 5.
	  	Termination.	  	10
			
	 6.
	  	Compensation Upon Termination.	  	11
			
	 7.
	  	Restrictions on Transfer.	  	13
			
	 8.
	  	Repurchase of Unvested Shares.	  	14
			
	 9.
	  	Put/Call Rights on Vested Shares.	  	15
			
	 10.
	  	Permitted Transfers; Prohibited Transfers.	  	16
			
	 11.
	  	Legend; Stop Transfer Instructions.	  	16
			
	 12.
	  	Survival of Certain Sections.	  	17
			
	 13.
	  	Ownership.	  	17
			
	 14.
	  	Market Standoff.	  	17
			
	 15.
	  	Escrow of Shares.	  	18
			
	 16.
	  	Assignment and Binding Effect.	  	18
			
	 17.
	  	Notices.	  	18
			
	 18.
	  	Governing Law.	  	18
			
	 19.
	  	Amendment and Waiver.	  	18
			
	 20.
	  	Severability.	  	19
			
	 21.
	  	Interpretation; Construction.	  	19
			
	 22.
	  	Attorneys’ Fees.	  	19
			
	 23.
	  	Cumulative Remedies.	  	19
			
	 24.
	  	Further Assurances.	  	19
			
	 25.
	  	Counterparts.	  	20

  

 i 

 EMPLOYMENT AGREEMENT 
 This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into on February 18, 2004, by and between JAZZ PHARMACEUTICALS, INC., a Delaware corporation (the
“Company”), and BRUCE C. COZADD (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a
“Party”. 
 RECITALS 
 A. The Company retained the services of the Executive pursuant to an offer letter, dated April 1, 2003, as amended (the “Offer Letter”). 
 B. In connection with the Company’s sale of Series A Preferred Stock to investors, the Executive and the Company entered into the Stock Restriction
Agreement, dated April 30, 2003, as amended (the “Stock Restriction Agreement”). 
 C. The Executive and the
Company entered into the Common Stock Purchase Agreement, dated October 30, 2003 (the “Stock Purchase Agreement” and, together with the Stock Restriction Agreement, the “Stock Agreements”)

 D. Certain parties are now proposing to purchase shares of the Company’s Series B Preferred Stock and Series B Prime Preferred Stock.

 E. The Company and the Executive wish to enter into this Agreement in order to (i) amend and restate the terms and conditions of the
Company’s retention of the Executive’s services and (ii) amend and restate the terms and conditions of certain restrictions on the capital stock of the Company held by the Executive. 
 AGREEMENT 
 NOW THEREFORE, FOR GOOD
AND VALUABLE CONSIDERATION, THE PARTIES AGREE AS FOLLOWS: 
  

	 	1.	Integration. 

 This Agreement
and the Transactional Agreements constitute the entire agreement between the Company and the Executive regarding the subject matter hereof and thereof and supersede and replace any and all prior oral and written negotiations, correspondence,
understandings and agreements between the parties regarding the subject matter hereof and thereof; provided, however, the Offer Letter, the Stock Agreements, and the Employee Confidential Information and Inventions Agreement between the Company and
the Executive shall remain in full force and effect. To the extent this Agreement conflicts with the Offer Letter or the Stock Agreements, this Agreement controls. To the extent this Agreement conflicts with the Employee Confidential 

 
Information and Inventions Agreement, the Employee Confidential Information and Inventions Agreement controls. To the extent this Agreement conflicts with
the terms of the Company’s employee handbook in effect from time to time, this Agreement controls. For purposes of this Agreement, the “Transactional Agreements” shall mean the Preferred Stock Purchase Agreement (the
“Purchase Agreement”) dated January 27, 2004 among the Company and other parties identified therein, the Amended and Restated Investor Rights Agreement (the “Investor Rights Agreement”) of even
date herewith among the Company and other parties identified therein, the Amended and Restated Right of First Refusal and Co-Sale Agreement (the “Right of First Refusal Agreement”) of even date herewith among the Company and
the parties identified therein, and the Amended and Restated Voting Agreement (the “Voting Agreement”) of even date herewith among the Company and the parties identified therein, each as may be amended in accordance with its
terms. 
  

	 	2.	Definitions. 

 For purposes of this
Agreement, the following terms shall have the following meanings: 
 2.1. “Affiliate” shall mean, with respect to any
Person, a Person directly or indirectly controlling, controlled by, or under common control with, such Person. 
 2.2.
“Annual Bonus Rate for the Termination Year” shall mean: 
 2.2.1. if the Executive has not previously
received an annual bonus at the time of termination, the Executive’s Bonus Rate; and 
 2.2.2. if the Executive has previously received
an annual bonus payment at the time of termination, the lesser of the Executive’s Bonus Rate and the product of the Managers’ Bonus Rate for the year in which the termination occurs times the Executive’s target bonus percentage for
the year in which the termination occurs. 
 2.3. “Annual Bonus Rate for the Reference Year” shall mean:

 2.3.1. if the Executive has not previously received an annual bonus at the time of termination, the Executive’s Bonus Rate; and

 2.3.2. if the Executive has previously received an annual bonus payment at the time of termination, the lesser of the Executive’s
Bonus Rate and the product of the Managers’ Bonus Rate for the Reference Year times the Executive’s target bonus percentage for the year in which the termination occurs. 
 2.4. “Call” shall mean the right of the Company to buy Vested Shares pursuant to Section 9.4. 
  

 2 

 2.5. “Cause” shall mean the occurrence of any of the following events:

 2.5.1. the Executive’s willful misconduct or gross negligence that is materially injurious to the Company; 
 2.5.2. the Executive’s conviction or plea of guilty or nolo contendere to any felony or crime involving moral turpitude; 
 2.5.3. the Executive’s commission of any act of fraud with respect to the Company; 
 2.5.4. the Executive’s willful violation of any federal or state securities law; or 
 2.5.5. the Executive’s willful and continued failure to perform the Executive’s job duties after 30 days’ written notice from the Board
setting forth in detail the specific respects in which it believes the Executive has willfully and not substantially performed such job duties and a failure by Executive to cure within such 30-day period if capable of being cured. 
 2.6. “Change of Control” means (i) a sale of all or substantially all of the assets of the Company to a Person
that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or to a Group that does not include an Initial B/P Holder or an Affiliate of an Initial B/P Holder, or a sale of all or substantially all of the assets of the Company
to a Person in which the stockholders of the Company immediately prior to such transaction do not control more than 50% of the voting power immediately following the transaction; (ii) a transaction or series of related transactions by the
Company (other than transaction(s) determined by the Board of Directors to be primarily for cash financing purposes) or by any stockholder or stockholders of the Company resulting in more than 50% of the voting power of the Company being held by a
Person that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or by a Group that does not include an Initial B/P Holder or an Affiliate of an Initial B/P Holder; (iii) a merger or consolidation of the Company with or
into a Person that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or with or into a Group that does not include an Initial B/P Holder or an Affiliate of an Initial B/P Holder, if and only if, after such merger or
consolidation, directors of the Company immediately prior to such merger or consolidation do not constitute a majority of the directors of the surviving entity or its parent. 
 2.7. “Change of Control Severance” shall mean: 
 2.7.1. an amount, payable in one lump sum at the time of termination, equal to the product of (a) one-twelfth of the Executive’s annual base
salary in effect at the time of termination times (b) the number of months included in the Severance Period, subject to standard deductions and withholdings; 
  

 3 

 2.7.2. an amount, payable in one lump sum at the time of termination, equal to the product of the
Executive’s Bonus Rate times the Executive’s base salary in effect at the time of termination prorated, on the basis of a 365-day year, to reflect the number of days elapsed in the year of Executive’s termination prior to and
including the date of termination; 
 2.7.3. an amount, payable in one lump sum at the time of termination, equal to the product of
(a) one-twelfth of the Executive’s annual base salary as in effect at the time of termination times (b) the Executive’s Bonus Rate times (c) the number of months included in the Severance Period, subject to standard
deductions and withholdings; and 
 2.7.4. an amount, payable monthly, equal to the monthly COBRA payments to continue medical and dental
benefits for a period ending on the earlier of (a) the end of the last month of the Severance Period and (b) the date on which the Executive is covered by medical and dental insurance through his or her own employment. 
 2.8. “Common Shares” shall mean the shares of Common Stock that the Executive now owns or hereafter acquires from the Company.

 2.9. “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties under
this Agreement because the Executive has become permanently disabled within the meaning of any policy of disability income insurance then in force covering employees of the Company. In the event the Company has no policy of disability income
insurance in force covering employees of the Company, the term “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement by reason of any incapacity, physical
or mental, which the Board, based upon medical advice or an opinion provided by a licensed physician acceptable to the Board and the Executive, determines to have incapacitated the Executive from performing all of the Executive’s usual services
for the Company for a period of at least 120 days during any 12 month period (whether or not consecutive) and is expected to continue to incapacitate the Executive thereafter. Based upon such medical advice or opinion, the determination of the Board
shall be final and binding and the date such determination is made shall be the date of such Complete Disability for purposes of this Agreement. 
 2.10. “Executive’s Bonus Rate” shall mean: 
 2.10.1. if the Executive has not previously
received an annual bonus, the target bonus percentage for the year in which the termination occurs; 
  

 4 

 2.10.2. if the Executive has previously received one annual bonus payment at the time of termination,
that percentage calculated by dividing the annual bonus actually paid for the year to which the bonus relates by the salary actually paid for such year; or 
 2.10.3. if the Executive has received more than one annual bonus payment at the time of termination, the average over the prior two years of the percentage calculated by dividing the bonus actually paid for the year
to which the bonus relates by the salary actually paid for such year. 
 2.11. “Fair Market Value” shall mean the
value of the Shares determined in good faith by the Board of Directors, provided that (a)(i) if the Shares are listed on any established stock exchange or a national market system, their fair market value shall be the average of the closing
sales price for the Shares as quoted on such system or exchange (or the largest such exchange) over the 5-trading-day period ending immediately prior to the date of the Notice of Put/Call Exercise, as reported in the Wall Street Journal or similar
publication, and (ii) if the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, their fair market value shall be the mean between the closing bid and asked prices for the Shares on the date of the
Notice of Put/Call Exercise (or if there are no quoted prices for such date, then for the last preceding business day on which there were quoted prices), and (b) if clauses (a)(i) or (a)(ii) are not applicable, the Board of Directors shall
apply valuation techniques generally used by reputable investment bankers (without giving effect to any premium that might be paid by a strategic buyer in an acquisition) to determine the value of the Shares as of the date of the Notice of Put/Call
Exercise. 
 2.12. “Founder Shares” shall mean shares of Common Stock that the Executive owns immediately prior to the
Initial Closing (as defined in the Purchase Agreement). 
 2.13. “Good Reason” shall mean the occurrence of any of the
following events without the Executive’s written consent: 
 2.13.1. a substantial diminution by the Company in the nature or status of
the Employee’s responsibilities or an adverse change in title or reporting level as they exist on the date of this Agreement, or the addition of responsibilities of a nature or status inconsistent with the office of Executive Chairman of a
company such as the Company; 
 2.13.2. the relocation of the Company’s executive offices or principal business location to a point more
than 20 miles (or greater distance with the prior written consent of the Executive) from the Company’s current facilities in Palo Alto, California; 
  

 5 

 2.13.3. a reduction by the Company of the Executive’s base salary or bonus rate as initially set
forth herein or as the same may be increased from time to time, other than a comparable across-the-board reduction in base salary or bonus rate of (a) the Company’s employees generally, or (b) the senior officers generally (if
approved by a majority of the Company’s senior officers), in each case as a result of the Company’s need to conserve capital; 
 2.13.4. any action by the Company (including the elimination of benefit plans without providing substitutes thereof or the reduction of the Executive’s benefits thereunder) that would materially diminish the aggregate value of the
Executive’s fringe benefits as they exist at such time, other than a comparable across-the-board diminution in fringe benefits of (a) the Company’s employees generally, or (b) the senior officers generally (if approved by a
majority of the Company’s senior officers), in each case as a result of the Company’s need to conserve capital; or 
 2.13.5. a
material breach of this Agreement by the Company. 
 2.14. “Group” means two or more Persons acting together as a
partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of or voting securities of the Company. 
 2.15. “Initial B/P Holder” means a Person that holds any shares of Series B/P Preferred as of the date the first share of Series B/P Preferred is issued. 
 2.16. “Manager” shall mean any of Samuel R. Saks, Bruce C. Cozadd, Robert M. Myers, Matthew K. Fust, Carol A. Gamble and Janne L.
T. Wissel. 
 2.17. “Managers’ Bonus Rate” shall mean the average for all Managers of X/Y where X
is the actual bonus paid for the year in which a termination occurs or the Reference Year, as appropriate, and Y is the target bonus for such year; but including only those Managers who were employed for the entire year; provided that if there were
no Managers employed for the entire year, then the Managers’ Bonus Rate shall equal the Executive’s Bonus Rate. 
 2.18.
“Management Team” shall mean the Chairman of the Board (if the Chairman is an officer of the Company), the Chief Executive Officer, and the management employees reporting directly to the Chairman or the Chief Executive
Officer, in office immediately prior to a Significant Transaction. 
 2.19. “Original Purchase Price” for each Share
shall mean the price paid by the Executive for that Share (as appropriately adjusted for any stock combination, stock split, stock dividend, recapitalization or other similar transaction after the date hereof). 
  

 6 

 2.20. “Person” means an individual, partnership, corporation, business trust,
joint stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature, and “control” shall have the meaning given such term under Rule 405 of the Securities Act of 1933, as amended
(the “Securities Act”). 
 2.21. “Preferred Shares” shall mean the shares of the Company’s Series A
Preferred Stock and Series B Preferred Stock (or Common Stock issuable upon conversion of the Series A Preferred Stock or Series B Preferred Stock) that the Executive now owns or hereafter acquires from the Company. 
 2.22. “Put” shall mean the right of the Executive or his/her estate to require the Company to buy Vested Shares pursuant to
Section 9.4. 
 2.23. “Reference Year” shall mean the year following the year in which the
Executive’s employment termination occurs. 
 2.24. “Regular Severance” shall mean: 
 2.24.1. an amount, payable in accordance with the Company’s customary payroll practices, for each month during the Severance Period, equal to
one-twelfth of the Executive’s base salary in effect at the time of termination, subject to standard deductions and withholdings; plus 
 2.24.2. an amount, payable monthly, equal to the monthly COBRA payments to continue medical and dental benefits for a period ending on the earlier of (a) the end of the last month of the Severance Period and (b) the date on which
the Executive is covered by medical and dental insurance through his or her own employment; 
 2.24.3. an amount, payable at such time as
bonus payments are due to other employees of the Company for the year in which the termination occurs, equal to the sum of (a) one-half of the Annual Bonus Rate for the Termination Year times Executive’s base salary in effect at the time
of termination prorated, on the basis of a 365-day year, to reflect the number of days elapsed in the year of Executive’s termination prior to and including the date of termination plus (b) the Annual Bonus Rate for the Termination Year
times Executive’s base salary in effect at the time of termination prorated, on the basis of a 365-day year, to reflect the number of days remaining in the year of Executive’s termination after the date of termination; and 
 2.24.4. an amount, payable at such time as bonus payments are due to other employees of the Company for the Reference Year, equal to the Annual Bonus
Rate for the Reference Year times the Executive’s base salary in effect at the time of termination prorated, on the basis of a 365-day year, to reflect the number of days elapsed in the year of Executive’s termination prior to and
including the date of termination. 
  

 7 

 2.25. “Right of Repurchase” shall mean the Company’s right to repurchase
Unvested Shares pursuant to Section 8.1. 
 2.26. “Severance Period” shall mean 12 months plus one additional
month for each quarter, up to a maximum of 12, that the Executive has been employed by the Company in excess of two years. For avoidance of doubt, the maximum Severance Period is two years. 
 2.27. “Shares” shall mean the Common Shares and the Preferred Shares. 
 2.28. “Significant Transaction” shall mean a merger or consolidation of the Company with or into any Person, or an
acquisition of all of the business of another Person regardless of form, if and only if, after such merger, consolidation or acquisition, directors of the Company immediately prior to such merger, consolidation or acquisition constitute a majority
of the directors of the surviving entity or its parent. 
 2.29. “Transactional Agreements” shall have
the meaning assigned in Section 1. 
 2.30. “Unvested Founder Shares” shall mean the Founder Shares held by the
Executive that are then subject to the Right of Repurchase. 
 2.31. “Vested Shares” shall mean the Shares held by the
Executive that are not subject to the Right of Repurchase. 
 2.32. “Vesting Base Date” shall mean the date(s) set
forth on Exhibit A. 
  

	 	3.	Employment. 

 3.1. Term. The
Company hereby employs the Executive, and the Executive hereby accepts employment by the Company, upon the terms and conditions set forth in this Agreement. The term of the Executive’s employment under the terms and conditions of this Agreement
shall continue until the fifth anniversary of the date of this Agreement, subject to the provisions of Section 5. 
 3.2.
Title. The Executive shall have the title of Executive Chairman of the Company and shall also serve in such other capacity or capacities as the Board of Directors of the Company (the “Board”) may from time to
time prescribe. The Executive shall report to the Board. 
 3.3. Duties. The Executive shall do and perform all services, acts
or things necessary or advisable to manage and conduct the business of the Company and which are normally associated with the position of Executive Chairman, consistent with the bylaws of the Company and as required by the Board. 
  

 8 

 3.4. Location. Unless the Parties otherwise agree in writing, during the term of
Executive’s employment under this Agreement, the Executive shall perform the services Executive is required to perform pursuant to this Agreement at the Company’s offices, located in Palo Alto, California; provided, however, that the
Company may from time to time require the Executive to travel temporarily to other locations in connection with the Company’s business. 
 3.5. Commitment. Unless otherwise agreed to in advance by the Company’s Board of Directors, during the Executive’s employment by the Company, the Executive shall devote 75% of Executive’s business energies,
interest, abilities and productive time to the proper and efficient performance of Executive’s duties under this Agreement; provided, however, the Executive may engage in other outside business activity listed on Exhibit B hereto. If the
Executive wishes to engage in any other outside work, the Executive agrees to notify and consult with the Board of Directors and shall not engage in such other outside work without the prior approval of the Board of Directors. 
  

	 	4.	Compensation of the Executive. 

 4.1. Base Salary. The Company shall pay the Executive a base salary at a rate of three-hundred seventy-five thousand dollars ($375,000) per year (based on full-time employment) for calendar year 2004, subject to increases
approved by the Board of Directors for calendar years thereafter, less payroll deductions and all required withholdings, payable in regular periodic payments in accordance with Company policy. Such base salary shall be prorated for any partial year
of employment on the basis of a 365-day year or for part-time employment. 
 4.2. Bonus. In addition to Executive’s base
salary, the Executive will be entitled to receive a bonus determined in accordance with an executive bonus plan established by the Board of Directors. The target bonus for the Executive shall be 50% (subject to increases approved by the Board of
Directors) of the annual base salary rate (pro-rated for part-time employment). 
 4.3. Employment Taxes. All of the
Executive’s compensation shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company. 
 4.4. Benefits. The Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to
participate in benefits under any executive benefit plan or arrangement which may be in effect from time to time and made available to the Company’s executive or key management employees. 
  

 9 

 4.5. Vacation. Executive shall be eligible for paid time off and holidays in accordance
with the Company’s standard policies for executive employees. 
 4.6. Expenses. The Company shall reimburse Executive for
all reasonable, documented out-of-pocket business expenses incurred on behalf of the Company in the performance of the Executive’s duties. 
  

	 	5.	Termination. 

 5.1. Termination by the
Company. The Executive’s employment with the Company may be terminated under the following conditions: 
 5.1.1. Death or
Disability. The Executive’s employment with the Company shall terminate effective upon the date of the Executive’s death or Complete Disability. 
 5.1.2. For Cause. The Company may terminate the Executive’s employment under this Agreement for Cause by delivery of notice to the Executive specifying the Cause or Causes relied upon for such
termination. Any notice of termination given pursuant to this Section 5.1.2 shall effect termination as of the future date specified in such notice or, in the event no such date is specified, on the last day of the month in which such notice is
delivered or deemed delivered as provided in Section 15 below. 
 5.1.3. Without Cause. The Company may terminate the
Executive’s employment under this Agreement at any time for any reason other than for “Cause” by delivery of notice of such termination to the Executive. Any notice of termination given pursuant to this Section 5.1.3 shall effect
termination as of the future date specified in such notice or, in the event no such date is specified, on the last day of the month in which such notice is delivered or deemed delivered as provided in Section 15 below. 
 5.2. Termination By The Executive. The Executive may terminate the Executive’s employment with the Company under the following
conditions: 
 5.2.1. For Good Reason. The Executive may terminate the Executive’s employment under this Agreement for
Good Reason effective 30 days following delivery of notice to the Company specifying the Good Reason relied upon by the Executive for such termination, provided that such notice is delivered within three (3) months following the occurrence of
any event or events constituting Good Reason, and failure of the Company to cure the event which constitutes Good Reason within such 30-day period. 
  

 10 

 5.2.2. Without Good Reason. The Executive may terminate the Executive’s employment
hereunder for other than Good Reason effective upon 30 days’ notice to the Company. 
 5.3. Termination by Mutual Agreement of the
Parties. The Executive’s employment pursuant to this Agreement may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such agreement.
Any agreement of termination entered into pursuant to this Section 5.3 shall effect termination as of the date specified in such agreement or, in the event no such date is specified, on the last day of the month in which such agreement is
delivered or deemed delivered as provided in Section 15 below. 
 5.4. Termination of Obligations. In the event of the
termination of the Executive’s employment hereunder and pursuant to this Section 5, the Company shall have no obligation to pay Executive any base salary, bonus or other compensation or benefits, except as otherwise provided in this
Agreement or for benefits due to the Executive (and/or the Executive’s dependents) under the terms of the Company’s benefit plans or for reimbursement of reasonable, documented business expenses. 
  

	 	6.	Compensation Upon Termination. 

 6.1.
Death or Complete Disability. If the Executive’s employment is terminated pursuant to Section 5.1.1 (Death or Disability), the Company shall pay the Executive’s accrued base salary and accrued and unused vacation
benefits earned through the date of termination and accrued bonus (if any), subject to standard deductions and withholdings, at the rate in effect at the time of termination to Executive and/or Executive’s heirs, and, except as provided in
Section 9.2, the Company shall thereafter have no further obligations to the Executive and/or Executive’s estate under this Agreement. 
 6.2. For Cause or Without Good Reason. If the Executive’s employment is terminated pursuant to Section 5.1.2 (For Cause) or 5.2.2 (Without Good Reason), the Company shall pay the Executive’s accrued base salary
and accrued and unused vacation benefits earned through the date of termination, subject to standard deductions and withholdings, at the rate in effect at the time of the notice of termination to Executive, and the Company shall thereafter have no
further obligations to the Executive under this Agreement. 
 6.3. Without Cause or For Good Reason. If the Executive’s
employment is terminated pursuant to Section 5.1.3 (Without Cause) or 5.2.1 (With Good Reason) (other than With Good Reason due to a relocation as described in Section 2.13.2 which event is covered in Section 6.5), the Executive shall
be entitled to the Executive’s base salary and accrued and unused vacation benefits earned through the date of termination, in each case subject to standard deductions and withholdings. In addition, 

  

 11 

 
upon the Executive’s furnishing to the Company an effective waiver and release of claims (a form of which is attached hereto as Exhibit C),
the Company shall pay the Executive Regular Severance for the period and in the manner set forth in the definition thereof. 
 6.4.
Following a Significant Transaction. If the employment of 50% or more of the members of the Management Team, including the employment of the Chief Executive Officer, is terminated in connection with a Significant Transaction, and
Executive is employed by the Company on the first anniversary of the effective date of the Significant Transaction, Executive shall have an option (exercisable by delivering notice of exercise to the Company) to terminate his or her employment. If
the Executive opts to terminate his or her employment pursuant to this Section 6.4, upon the Executive’s furnishing to the Company an effective waiver and release of claims (a form of which is attached hereto as Exhibit C), the
Company shall pay the Executive Regular Severance for the period and in the manner set forth in the definition thereof. 
 6.5. Change
of Control Severance. 
 6.5.1. If any of the following occur, upon the Executive’s furnishing to the Company an effective
waiver and release of claims (a form of which is attached hereto as Exhibit C), the Company shall pay the Executive Change of Control Severance for the period and in the manner set forth in the definition thereof: 
 (i) the Executive’s employment is terminated pursuant to Section 5.2.1 (With Good Reason) due to a relocation as described in
Section 2.13.2; 
 (ii) the Executive’s employment is terminated pursuant to Section 5.1.3 (Without Cause) or
Section 5.2.1 (With Good Reason) in connection with a Change of Control or Significant Transaction; or 
 (iii) the employment of 50% or
more of the members of the Management Team, including the employment of the Chief Executive Officer, is terminated in connection with a Significant Transaction and, prior to the first anniversary of the effective date of the Significant Transaction,
the Executive’s employment is terminated by the Company pursuant to Section 5.1.3 (Without Cause) or Section 5.2.1 (for Good Reason). 
 6.5.2. In the event there is a Change of Control of the Company and provided Executive is employed by the Company on the first anniversary of the effective date of the Change of Control, Executive shall have an option
(exercisable by delivering notice of exercise to the Company) to terminate his or her employment. If the Executive opts to terminate his or her employment pursuant to this Section 6.5.2, at the time of such termination the Company shall pay the
Executive Regular Severance for the period and in the manner set forth in the definition thereof. 
  

 12 

 6.5.3. In the event that any payment received or to be received by the Executive pursuant to this
Agreement or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and
(ii) but for this Section 6.5.3, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then, subject to the provisions of Section 6.5.4 hereof, such Payment shall be reduced
to the largest amount which would result in no portion of the Payment being subject to the Excise Tax. The determination of any required reduction pursuant to this Section 6.5.3 shall be made by a nationally recognized certified public
accounting firm used by the Company immediately prior to the effective date of a change of control or, if such firm declines to serve, such other nationally recognized certified public accounting firm as may be designated by the Company (the
“Accounting Firm”) in its discretion. All fees and expenses of the Accounting Firm shall be borne by the Company. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. If the Accounting
Firm determines that a reduction is required by this Section 6.5.3, the Executive, in his/her discretion, may determine which portion of the Payment shall be reduced to the extent necessary so that no portion thereof shall be subject to the
Excise Tax, and the Company shall pay such reduced amount to him/her. If the Internal Revenue Service (the “IRS”) determines that a Payment is subject to the Excise Tax, then Section 6.5.4 hereof shall apply, and the
enforcement of Section 6.5.4 shall be the exclusive remedy to the Company for a failure by the Executive to reduce the Payment so that no portion thereof is subject to the Excise Tax. 
 6.5.4. If, notwithstanding any reduction described in Section 6.5.3 (or in the absence of any such reduction), the IRS determines that the Executive
is liable for the Excise Tax as a result of the receipt of a Payment, then the Executive shall be obligated to pay back to the Company, within thirty (30) days after final IRS determination, an amount of the Payment equal to the
“Repayment Amount”. The Repayment Amount with respect to a Payment shall be the smallest such amount, if any, as shall be required to be paid to the Company so that the Executive’s net proceeds with respect to any
Payment (after taking into account the payment of the Excise Tax imposed on such Payment) shall be maximized. If the Excise Tax is not eliminated pursuant to this Section 6.5.4, the Executive shall pay the Excise Tax. 
  

	 	7.	Restrictions on Transfer. 

 Subject to the
other provisions hereof, and except as permitted under the Right of First Refusal Agreement or Voting Agreement, Executive shall not sell, pledge or otherwise transfer to any person or entity any Shares or any interest therein until the earlier of
(a) the fifth anniversary of the Initial Closing (as defined in the Purchase Agreement), and (b) the closing of a Change of Control. 
  

 13 

	 	8.	Repurchase of Unvested Shares. 

 8.1.
Repurchase Right. Except as provided in Section 8.2 below, if the Executive’s employment is terminated, the Company has a right (but not an obligation) to repurchase (the “Right of Repurchase”) all or
any portion of the Founder Shares held by the Executive for a price per share equal to the Original Purchase Price; provided, however, that the Right of Repurchase shall expire with respect to 1/48th of the Founder Shares on each monthly anniversary
following the Vesting Base Date for such Founder Shares (i.e., so that the Right of Repurchase shall have expired with respect to all of such Common Shares 48 months following the Vesting Base Date). 
 8.2. Acceleration of Lapse of Repurchase Rights Upon Certain Events. Notwithstanding the provisions of Section 8.1, 
 8.2.1. if, prior to a Change of Control (and not in connection with such Change of Control), the Executive’s employment is terminated pursuant to
Section 5.1.3 (Without Cause) or Section 5.2.1 (For Good Reason) at any time prior to the expiration of the Right of Repurchase, then one-fourth (1/4th) of the Founder Shares (or the actual number of Unvested Founder Shares
immediately prior to such termination event, if less) will become Vested Shares immediately prior to such termination event, and the Company will have no Right of Repurchase with respect to such Founder Shares; 
 8.2.2. if, in connection with a Change of Control or within twelve (12) months following the closing of a transaction which constitutes a Change of
Control, the Executive’s employment is terminated pursuant to Section 5.1.3 (Without Cause) or 5.2.1 (For Good Reason), then all of the then Unvested Founder Shares held by the Executive will become Vested Shares immediately prior to such
termination event, and the Company will have no Right of Repurchase with respect to any of the Founder Shares; 
 8.2.3. if the
Executive’s employment is terminated as described in Section 6.5.1.(ii) or Section 6.5.1(iii), then all of the then Unvested Founder Shares held by the Executive will become Vested Shares immediately prior to such termination event,
and the Company will have no Right of Repurchase with respect to any of the Founder Shares; or 
 8.2.4. if, more than twelve
(12) months following the closing of a transaction which constitutes a Change of Control, the Executive’s employment is terminated pursuant to Section 5.1.3 (Without Cause) or 5.2.1 (For Good Reason), then one-fourth (1/4th) of
the Founder Shares (or the actual number of Unvested Founder Shares immediately prior to such termination event, if less) will become Vested Shares immediately prior to such termination event, and the Company will have no Right of Repurchase with
respect to such Founder Shares. 
  

 14 

 8.3. Procedure to Exercise Right of Repurchase. To exercise its Right of Repurchase, the
Company must give notice (“Notice of Repurchase”) to the Executive (or his/her estate) within 90 days after the date of the Executive’s termination and must purchase the Unvested Founder Shares no later than 10 days after the date of
the notice. 
  

	 	9.	Put/Call Rights on Vested Shares. 

 9.1. Termination For Cause or Without Good Reason. Until the fifth anniversary following the Initial Closing, if the Executive’s employment is terminated pursuant to Section 5.1.2 (For Cause)
or 5.2.2 (Without Good Reason), the Company will have the right (but not the obligation) to Call any or all of the Vested Shares at a price per share equal to the lower of their (a) Original Purchase Price or (b) Fair Market Value.

 9.2. Termination due to Death or Complete Disability. Until the fifth anniversary following the Initial Closing, if the
Executive’s employment is terminated pursuant to Section 5.1.1 (Death or Disability), the Company will have the right (but not the obligation) to Call, and the Executive or Executive’s estate will have the right (but not the
obligation) to Put, any or all of the Vested Shares at a price per share equal to their Fair Market Value. 
 9.3. Termination Without
Cause or For Good Reason. Until the fifth anniversary following the Initial Closing, if the Executive’s employment is terminated pursuant to Section 5.1.3 (Without Cause) or 5.2.1 (For Good Reason), the Company will have the right
(but not the obligation) to Call any or all of the Vested Shares at a price per share equal to their Fair Market Value. 
 9.4.
Procedure to Exercise Put/Call Rights. To exercise its right to Call Vested Shares, the Company must give notice (“Notice of Put/Call Exercise”) to the Executive (or his/her estate) within the later of
(a) 90 days after the date of the Executive’s termination and (b) if the Executive purchases the Vested Shares pursuant to an option exercise after the date of the Executive’s termination, 30 days after the date of such purchase;
and the Company must purchase the Vested Shares no later than 10 days after the date of the notice (unless the Executive or his/her estate, in his, her or its discretion, agrees to a longer period). To exercise its right to Put Vested Shares, the
Executive or his/her estate must give notice (“Notice of Put/Call Exercise”) to the Company within 395 days after the date of the Executive’s termination. The Company will purchase the Vested Shares no later than 30 days
after the date of the notice (unless the Executive or his/her estate, in his, her or its discretion, agrees to a longer period). 
 9.5.
Termination of Call Right. The Company’s right to Call the Vested Shares shall terminate upon the closing of a Change of Control. 
  

 15 

	 	10.	Permitted Transfers; Prohibited Transfers. 

 10.1. Permitted Transfers. The restriction on transfer under Section 7 and the Company’s right to Call Vested Shares under Section 9.4 shall not apply to: 
 10.1.1. any transfer of Shares to the ancestors, descendants, spouse or domestic partner of Executive, or to trusts for estate planning purposes for the
benefit of such persons or the Executive; 
 10.1.2. any transfer of Shares by the laws of descent or distribution; 
 10.1.3. after the fourth anniversary of the date of the Initial Closing (as defined in the Purchase Agreement), up to 20% of the Shares then held by the
Executive, provided that the Company’s Common Stock has been listed on an established stock exchange or a national market system for at least one year; 
 10.1.4. any transfer of Shares pursuant to, and in accordance with, Section 4 of the Right of First Refusal Agreement or Section 2 of the Voting Agreement; and 
 10.1.5. any sale of Shares pursuant to an effective registration statement under the Securities Act of 1933, as amended, in accordance with the Investor
Rights Agreement. 
 The Shares transferred under Section 10.1.1 or 10.1.2 shall remain “Shares” for all purposes of this
Agreement, the transferee shall be treated as the “Executive” for all purposes of this Agreement (other than with respect to matters related to employment) and, as a condition to any such transfer, the transferee shall be
required to agree in writing to be bound by the provisions of Sections 7, 8 and 9 of this Agreement. 
 10.2. Prohibited
Transfers. Any sale, pledge, or other transfer of Shares not made in conformance with this Agreement shall be null and void, shall not be recorded on the books of the Company and shall not be recognized by the Company. 
  

	 	11.	Legend; Stop Transfer Instructions. 

 11.1.
Legend. Each certificate representing Shares or issued to any person in connection with a transfer pursuant to Section 10.1.1 or 10.1.2 shall be endorsed with the following legend: 
 “THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN
EMPLOYMENT AGREEMENT BY AND BETWEEN THE 

  

 16 

 
HOLDER HEREOF (OR AN ASSIGNOR) AND THE COMPANY. A COPY OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.”

 11.2. Stop Transfer Instructions. The Executive agrees that the Company may instruct its transfer agent to impose transfer
restrictions on the shares represented by certificates bearing the legend referred to in Section 11.1 above to enforce the provisions of this Agreement and the Company agrees promptly to do so. The legend shall be removed upon termination of
Sections 7, 8 and 9 of this Agreement. 
  

	 	12.	Survival of Certain Sections. 

 Sections 1, 2 and 6 through 25 of this Agreement will survive the termination of Executive’s employment under this Agreement. 
  

	 	13.	Ownership. 

 Executive represents and
warrants that he or she is the sole legal and beneficial owner of the Shares subject to this Agreement and that no other person or entity has any interest (other than a community property interest) in such shares and that no consent of any other
person or entity is required by reason of any community property interest or otherwise to enter into this Agreement and carry out the provisions hereof. 
  

	 	14.	Market Standoff. 

 The Executive hereby
agrees that, if so requested by the Company or any representative of the underwriters in connection with the registration of a public offering of any securities of the Company under the Securities Act of 1933, as amended (the “Securities
Act”), the Executive shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Shares or other securities of the Company (a “Market Standoff”)
without the prior written consent of the Company and the underwriter’s representative for such period of time (a) not to exceed 180 days following the effective date of a registration statement of the Company filed under the Securities Act
in the case of the Company’s initial public offering or (b) commencing with the date the Company provides notice to the Executive of a proposed follow-on offering and ending 90 days after the effective date of the registration statement
or, in the event of a shelf registration, the date of the prospectus for such follow-on offering, as may be requested by the underwriter’s representative; provided, however, that the Executive shall not be required to agree to a Market Standoff
for a period of time that commences less than 30 days after the expiration of another period of time during which the Executive has agreed to a Market Standoff. The obligations of the Executive under this Section 14 shall be conditioned upon
similar agreements being in effect with each other stockholder who is an officer, director or, with respect only to the Company’s initial public offering, greater than 1% stockholder of the Company prior to such initial public offering.

  

 17 

	 	15.	Escrow of Shares. 

 Pursuant to the terms of
the Joint Escrow Instructions in substantially the form attached hereto as Exhibit D, until the expiration of Sections 7, 8 and 9 of this Agreement, the Shares issued under this Agreement shall be held by the Escrow Agent (as defined in such
Joint Escrow Instructions) along with a stock assignment executed in blank in the form attached hereto as Exhibit E. Upon request by the Company, the Executive will deliver the Shares to the Escrow Agent. 
  

	 	16.	Assignment and Binding Effect. 

 This
Agreement shall be binding upon and inure to the benefit of the Executive and the Executive’s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the
Executive’s duties under this Agreement, no employment obligations under this Agreement shall be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal
representatives. 
  

	 	17.	Notices. 

 All notices required or permitted
hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, or if not, then on
the next business day; (iii) one day after deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices to the Company shall be sent to the
Company’s principal place of business. All notices to the Executive shall be sent to the address as set forth on the signature page or at such other address as the Executive may designate by ten days advance notice to the Company. 

 

	 	18.	Governing Law. 

 This Agreement shall be
governed by, and construed in accordance with, the laws of the State of California excluding those laws that direct the application of the laws of another jurisdiction. 
  

	 	19.	Amendment and Waiver. 

 Any provision of this
Agreement may be amended or waived only by a written instrument signed by the Company (with approval of a majority of the Board of Directors) and the Executive. Any such waiver, amendment, modification or termination of any provision of this
Agreement shall be binding on all parties hereto and their respective successors and permitted assigns. 
  

 18 

	 	20.	Severability. 

 In the event one or more of
the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement
shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 
  

	 	21.	Interpretation; Construction. 

 The headings
set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but the Executive has been encouraged to consult with
Executive’s own independent counsel and tax advisors with respect to the terms of this Agreement. The Parties agree that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not
be employed in the interpretation of this Agreement. 
  

	 	22.	Attorneys’ Fees. 

 If any action at law
or in equity (including arbitration) is necessary to enforce or interpret the terms of the Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to
which such party may be entitled. 
  

	 	23.	Cumulative Remedies. 

 No right or remedy
herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or
otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 
  

	 	24.	Further Assurances. 

 The parties to this
Agreement agree to cooperate with the other parties, and to execute such further instruments, documents and agreements, and to give such further written assurances, as may be reasonably requested by the other parties, to carry into effect the intent
and purpose of this Agreement. 
  

 19 

	 	25.	Counterparts. 

 This Agreement may be
executed in two counterparts, each of which shall be deemed an original, all of which together shall constitute one and the same instrument. 
 [SIGNATURE PAGES FOLLOW] 
  

 20 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on February 18, 2004, to be effective
as of February 18, 2004. 
  

			
	JAZZ PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Samuel R. Saks

		 	Samuel R. Saks, Chief Executive Officer

  

			
	EXECUTIVE:
	
	 /s/ Bruce C. Cozadd

	Bruce C. Cozadd
		
	Address:	 	  

		 	  

 EXHIBIT A 
 VESTING BASE DATE 
 For shares of the Company’s Common Stock now held by the Executive, the
Vesting Base Date shall be April 1, 2003. 
 For shares of the Company’s Common Stock issued upon exercise by the Executive of an
option to purchase shares of the Common Stock (an “Option”), the Vesting Base Date shall be the vesting base date set forth in the Option agreement/notice of exercise. 
 For shares of the Company’s Common Stock hereafter acquired by the Executive from the Company, but not issued pursuant to an Option, the Vesting
Base Date shall be the date of acquisition of such shares. 

 EXHIBIT B 
 OTHER BUSINESS ACTIVITY 
 Cerus Corporation: Member of the Board of Directors and Chairman of the Audit Committee.

 Genencor International, Inc.: Member of the Board of Director and Chairman of the Audit Committee. 
 Non-profit organizations: 
 Board of Directors of Nueva School. 

Stanford Medical Imaging Advisory Board. 
 Other non-profit Boards of
Directors from time to time. 

 EXHIBIT C 
 RELEASE AND WAIVER OF CLAIMS 
 In consideration of the payments and other benefits set forth in
Section 6.4 of the Employment Agreement dated                     , 2004, to be effective as of
                    , 200     to which this form is attached, I,
                                        ,
hereby furnish JAZZ PHARMACEUTICALS, INC. (the “Company”) with the following release and waiver (“Release and Waiver”). 
 In exchange for the consideration provided to me by this Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its directors, officers, employees,
stockholders, partners, agents, attorneys, predecessors, successors, insurers, Affiliates, and assigns from any and all claims, demands, liabilities, and obligations. This general release includes, but is not limited to: (1) all claims arising
out of or in any way related to my employment with the Company or the termination of that employment; (2) all contractual claims, including claims for breach of contract, wrongful termination, or breach of the covenant of good faith and fair
dealing; (3) all tort claims, including claims for fraud, defamation, and emotional distress; and (4) all federal, state, and local statutory claims including claims for discrimination, harassment, attorneys’ fees or other claims
arising under the federal Civil Rights Act of 1964, as amended, the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”), or the California Fair
Employment and Housing Act. However, this general release does not extend to rights and benefits expressly provided for in the Employment Agreement, under the governing documents for any securities I own of record, and under any agreement, bylaw or
statute providing me with indemnification. 
 Except as provided in the Employment Agreement described above, I acknowledge and agree that
the Company already has paid me any and all salary, other wages, bonuses, commissions, incentives, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options or any other ownership interests in the Company I am owed,
and that no such further payments, amounts or interests are owed or will be owed. 
 I also acknowledge that I have read and understand
Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him
must have materially affected his settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to any claims I may have
against the Company. 

 I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that
this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. If I am 40 years of age or older upon
execution of this Release and Waiver, I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to claims under the ADEA which may
arise after this Release and Waiver is executed; (b) I have the right to consult with an attorney before executing this Release and Waiver (although I may choose voluntarily not to do so); and (c) I have twenty-one (21) days from the
date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); (d) I have seven (7) days following the execution of this
Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the seven (7) day revocation period has expired. 
 If I am less than 40 years of age upon execution of this Release and Waiver, I acknowledge that I have the right to consult with an attorney before
executing this Release and Waiver (although I may choose voluntarily not to do so); and (c) I have five (5) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may
choose voluntarily to execute this Release and Waiver earlier). 
 I agree neither to file nor to encourage or knowingly permit another to
file any claim, charge, grievance, complaint or action for any sort of monetary damages against the Company and other released parties set forth above concerning any matter covered by this Agreement, except as otherwise provided by law. 

 

					
	Date:	 	  
	 	  

		 		 	[TYPE NAME]

  

 2 

 EXHIBIT D 
 JOINT ESCROW INSTRUCTIONS 
 [Escrow Agent Name and Address] 
 Ladies and Gentlemen: 
 As escrow agent (the
“Escrow Agent”) for both Jazz Pharmaceuticals, Inc., a Delaware corporation, and any assignee (referred to collectively as the “Company”), and the undersigned purchaser of stock of the Company (the
“Executive”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Employment Agreement, dated as of
                    , 2004 (the “Agreement”) between the Company and the Executive (the
“Escrow”), in accordance with the following instructions: 
 1. In the event the Company and/or any assignee of the
Company exercises the Company’s Right of Repurchase (as defined in the Agreement), the Company shall give to Executive and you a written notice specifying the number of shares of stock to be purchased, the purchase price and the time for a
closing hereunder at the principal office of the Company. Executive and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 
 2. At the closing, you are directed (a) to date the stock assignments necessary for the transfer in question, (b) to fill in the number of
shares being transferred, and (c) to deliver the same, together with the certificate evidencing the shares of stock to be transferred, to the Company, against the simultaneous delivery to you of the purchase price (by cash, a check, promissory
note, wire transfer, cancellation of indebtedness or some combination thereof) for the number of shares of stock being purchased pursuant to the exercise of the Company’s Right of Repurchase. 
 3. Executive irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you hereunder and any
additions and substitutions to said shares. Executive does hereby irrevocably constitute and appoint you as Executive’s attorney-in-fact and agent for the term of this Escrow to execute with respect to such securities all documents necessary or
appropriate to make such securities negotiable and to complete any transaction herein contemplated, including but not limited to the filing with any applicable state blue sky authority of any required applications for consent to, or notice of
transfer of, the securities. Subject to the provisions of the Agreement and of this Escrow Agreement, Executive shall exercise all rights and privileges of a shareholder of the Company while the stock is held by you. 

 4. Upon written request of the Executive, but no more than once per calendar year, unless the
Company’s Right of Repurchase has been exercised, you will deliver to Executive a certificate or certificates representing so many shares of stock as are not then subject to the Company’s Right of Repurchase. Within one hundred
(100) days after cessation of Executive’s continuous employment by the Company, or any parent or subsidiary of the Company, you will deliver to Executive a certificate or certificates representing the aggregate number of shares held or
issued pursuant to the Agreement and not purchased by the Company or its assignees pursuant to exercise of the Company’s Right of Repurchase. 
 5. If at the time of termination of this escrow you should have in your possession any documents, securities or other property belonging to Executive, you shall deliver all of the same to Executive and shall be discharged of all further
obligations hereunder. 
 6. Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties
hereto. 
 7. You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be
protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may do or omit to do
hereunder as Escrow Agent or as attorney-in-fact for Executive while acting in good faith, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith. 
 8. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation,
excepting only orders or process of courts of law and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree, you shall not be liable to
any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered
without jurisdiction. 
 9. You shall not be liable in any respect on account of the identity, authorities or rights of the parties executing
or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 
 10. You shall
not be liable for the outlawing of any rights under the Statute of Limitations with respect to these Joint Escrow Instructions or any documents deposited with you. 
  

 4 

 11. You shall be entitled to employ such legal counsel and other experts as you may deem necessary
properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. 
 12. Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be an officer or agent of the Company or if you shall resign by written notice to each party. In the event of any such
termination, the Company shall appoint a successor Escrow Agent. 
 13. If you reasonably require other or further instruments in connection
with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments. 
 14. It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without
liability to anyone all or any part of said securities until such disputes shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the
time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings. 
 15. Any notice required or permitted hereunder shall be given pursuant to the notice provision set forth in the Agreement, provided any notice to be sent to Escrow Agent shall be sent to the address set forth on the signature page hereto,
or such other address as the Escrow Agent may provide from time to time in accordance with the terms of the Agreement. 
 16. By signing these
Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not become a party to the Agreement. 
 17. This instrument shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns. 
 18. These Joint Escrow Instructions shall be governed by, and construed and enforced in accordance with, the laws of the State of California. 

 

 5 

 19. All references to you, your and similar phrases shall refer to the Escrow Agent. 
  

									
	Dated:	 	  
	 		 	COMPANY:
				
		 		 		 	JAZZ PHARMACEUTICALS, INC.
					
		 		 		 	By:	 	  

					
		 		 		 	Name:	 	  

					
		 		 		 	Title:	 	  

				
	Dated:	 	  
	 		 	EXECUTIVE: [                    ]
				
		 		 		 	  

				
		 		 		 	  

				
		 		 		 	  

		 		 		 	Executive’s Spouse (if applicable)
				
	Dated:	 	  
	 		 	ESCROW AGENT:
		 		 		 	[                    ]
					
		 		 		 	By:	 	  

					
		 		 		 	Name:	 	  

					
		 		 		 	Title:	 	  

  

 6 

 EXHIBIT E 
 ASSIGNMENT SEPARATE FROM CERTIFICATE 
 FOR VALUE RECEIVED and pursuant to that certain Employment
Agreement between the undersigned (“Executive”) and Jazz Pharmaceuticals, Inc. (the “Company”) dated
                    , 2004 (the “Agreement”), Executive hereby sells, assigns and transfers unto the Company
                                        
(            ) shares of the Common Stock of the Company, standing in Executive’s name on the books of the Company and represented by Certificate(s) No(s).
            , and hereby irrevocably constitutes and appoints
                                        
to transfer said stock on the books of the Company with full power of substitution in the premises. THIS ASSIGNMENT MAY ONLY BE USED AS AUTHORIZED BY THE AGREEMENT. 
  

			
	Dated:                     	  	             Signature:

  

			
		
	By:	 	  

	Name:	 	  

	
	  

	Spouse (if applicable)

 Instructions: Please do not fill in any blanks other than the signature line. The purpose of this
assignment is to enable the Company to exercise its repurchase option set forth in the Agreement without requiring additional signatures on the part of Executive.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]